It appears that that Apple will be opening its first development center outside the United States in Israel. The move reportedly is not related to the possible acquisition of the Israeli company Anobit, which develops flash storage solutions that provide Apple’s iPhone and iPad a competitive advantage over its competitors. Aharon Aharon, a veteran in the Israeli high-tech scene, has reportedly been chosen to head the Israeli center and is undergoing training in Apple’s headquarters in the United States. Aharon refused to comment on the issue, saying only that he is in the United States. But at least three managers in Israel’s high-tech industry confirmed that Ahraon will be a senior vice president of engineering at Apple, and head Apple’s development activities in Israel.
Meanwhile, Apple is reportedly planning to acquire the Israeli company Anobit for hundreds of millions of dollars. If a deal will be completed, it will mark the biggest deal Apple has made since 1996 when it acquired NeXT, a company founded by Steve Jobs, for $429 million. The decision to set up an Apple R&D center in Israel could explain why it might be pursuing a large player like Anobit. Apple usually confines itself to small-scale acquisitions to obtain intellectual property.
Apple’s interest in Israel began in 2008, when an Israeli Technyon graduate joined the Company in Cupertino. The Israeli high tech employee joined Apple after fullfiling various positions at Intel and IBM. It was during that time that he met Aharon Aharon. Today he serves as Vice Preseident of Microchips in Apple. In the US Patent Registrar there are two patents registered on the Israeli high tech employee’s name, both registered in 2009, during the time he was already employed at Apple.
Talks between the Israel Medical Association and the Treasury fell short of yielding results last Wednesday, causing fears the doctors’ strike that began last week could continue into the new week. Doctors began a warning strike last Tuesday, treating only emergency cases.
The Ethics Committee of the Medical Histadrut (Federation) will now be permitted to sell the psycho-stimulant drug that treats attention-deficit hyperactivity disorder (ADHD) Ritalin (Methylphenidate) without a doctor’s prescription. 
The Assuta Medical Center in Tel Aviv opened last year wearing an impressive reputation. But lately, that reputation has been blemished.
A group of Jordanian pharmaceutical companies fear that operations of the Israeli company 
Around 70 doctors held a demonstration outside the Knesset in protest against the government’s decision. The doctors warned that moving the ward to a new location, as demanded by the haredim, “may end up costing us lives”.
Committee members toured the site Wednesday morning with 
Official rabbinic opinion allows surfing the Internet just for business purposes – but it’s a rule that apparently many are willing to break. According to a recently released study by the 
Last August saw the release of 4Wall LLC’s Jewish Internet Metric Study. It is a project aimed towards helping the Jewish community understand the “hurdles and opportunities” presented by the Internet. Certainly the idea behind this research flies in the face of fliers posted in residential ultra-orthodox areas in Israel which read, “××™× ×˜×¨× ×˜ ×ž×‘×™× ×¡×¨×˜×Ÿ” or ‘The Internet Brings Cancer‘.
You know when you surf the Web using your trusty 
We’re still on the ball, guys! Israeli scientist Ada Yonath has won the Nobel Prize in chemistry. She works at the 
This man, Dr. Alon Monsonego of Ben Gurion University, could be the face put on a real, workable Alzheimer’s vaccine. Alzheimer’s being one of the scariest, most devastating mental diseases imaginable where you pretty much die before you die since your mind is practically erased, this is very encouraging news. That, and cases have increased by 33% since 2005, with over 36 million people expected to be diagnosed with the disease this coming year.
How does it work? It tests for chemicals that are produced in cancer cells. They are ethylbenzene, decane, heptanol, and trimethylbenzne. 
It has often been assumed that after a heart attack, where by definition a piece of the heart dies for lack of blood and oxygen, the damage is irreparably permanent. However, Israel has done it again, this time by proving that, indeed, it is not. 
Adi has developed a tablet-based treatment for Type 1 diabetes, which tests show restores insulin production in animals. The drug is based on something called a Ras protein inhibitor. The Ras protein is found in 30% of all cancerous tumors, and completely disrupts a cell’s normal function. The inhibitor allows cells to continue with business as usual by taking the protein out of the equation. The drug was initially designed for patients with pancreatic cancer but Mor modified it to function for diabetics. 
Recent Comments